News | March 09, 2015

Biotronik Announces Results of BIOFLEX-I Trial at CRT Conference

Astron nitional stent found to reduce composite rate of procedure or stent-related major adverse events at 12 months to 2.1 percent

Astron, Biotronik, BIOFLEX-I, trial, peripheral stents, CRT 2015

February 23, 2015 – Biotronik announced the presentation of data from the iliac arm of the BIOFLEX-I clinical trial at the Cardiovascular Research Technologies (CRT) conference in Washington, D.C. The BIOFLEX-I trial is designed to support U.S. Food and Drug Administration (FDA) approval of the Astron self-expanding nitinol stent to treat patients suffering from common iliac or external iliac artery disease. National principal investigator for the study, Mark W. Burket, M.D., University of Toledo Medical Center, Ohio, presented results demonstrating that Astron had successfully met clinical endpoints for safety and efficacy.

For the iliac arm of the prospective, non-randomized, multi-center trial, Astron stents were implanted in 161 patients at 34 centers in the United States, Canada and Europe. The trial’s primary endpoint was the composite rate of procedure or stent-related major adverse events (MAEs) at 12 months after implantation. MAEs were defined as 30-day mortality, clinically-driven target lesion revascularization (TLR) and limb amputation at 12 months. During the “Breakfast Symposium: Best Abstracts” at CRT, Burket announced that the 12-month composite endpoint of MAE was only 2.1 percent (p<0.001), well below the stent’s performance goal of 15 percent, which was based on the trial results of similar self-expanding nitinol iliac stents.

Burket reported that secondary outcomes were also positive. In the trial, Astron’s 12-month primary patency rate was 89.8 percent, and the TLR rate was 1.4 percent. Additionally, patients demonstrated improvement in their ambulatory function and quality of life at 12 months compared to baseline as evaluated by the walking impairment questionnaire score, a common screening tool for peripheral arterial disease.

For more information: www.biotronik.com

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
Overlay Init